Avego BioScience Capital

Mid-to-Late Stage Venture and Crossover

INVESTMENT FOCUS

Prioritizing Specific Areas of Interest 


Industries

  • Therapeutics
  • Medical Devices, Tools, and Diagnostics
  • Services

Modalities

  • Gene Therapy / Gene Editing
  • Cell therapies
  • Biologics
  • Small molecules

Indications

  • Oncology
  • Neurology
  • Immunology
  • Ophthalmology
  • Rare disease

CORE PRINCIPLES

ABC Investment Approach


Unmet Need
We are most interested in technologies and products that are being developed to meet patient and clinician demands and improve on current treatment options. Ideal companies and product candidates have the potential for “best- or first-in-class” positioning.

Innovation
Our investment strategy is first and foremost evidence-based, with a strong preference for proprietary technologies and assets that represent advances in science. We value the ability to disrupt, coupled with strong protections such as an intellectual property advantage or other barriers to entry.

Management
Proven and effective leadership is a core component of our investment criteria. We believe that management teams with public company experience and prior successes in product development are often best positioned to deliver impactful and positive results.